University Hospital
Basel, 4031, Switzerland
NCT Number: NCT01187862
The purpose of this study is to assess whether a cocktail of seven approved drugs (so-called "Basel cocktail") can be used for simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.
Looking for future studies?
Notify Me18 year–45 year
Male
Interventional
Phase 1
Basel, 4031, Switzerland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
University Hospital, Basel, Switzerland
Other
Single-center, Randomized, Five-way Crossover Study to Investigate Low-dose Combinations of Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol, Chlorzoxazone and Midazolam ("Basel Cocktail") for Simultaneous Phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07560150
Insulin Aspart, Pharmacodynamics
Chula Vista, California, United States
View Trial DetailsNCT05142592
Pharmacokinetics, Safety Issues
Portland, Oregon, United States
View Trial DetailsNCT03911050
Human Health, Pharmacokinetics
Kannapolis, North Carolina, United States
View Trial DetailsNCT05328778
Pharmacokinetics
Guangzhou, Guangdong, China
View Trial Details